Indirect Costs
• Social, indirect, and intangible costs contribute to the overall economic consequences of PCA including (but not limited to) loss in work productivity, loss in earned income, caregiver expenses, and psychological distress. Studies on indirect costs associated with PCA are particularly scarce.
• Only two studies from the U.S. and Canada presented the indirect mortality costs (the cost of lost productivity due to premature death) associated with PCA. [23] [24] • Three studies, including two in the U.S. [25] [26] and one in the U.K., 27 examined the indirect costs of screening and treatment.
• Another U.S. study calculated the costs of ruling out cancer among patients with a false positive screen on the prostate specific antigen test or the digital rectal exam. 28 • The prevalence of PCA will increase as septuagenarians, octogenarians, and nonagenarians increase in number in the U.S., Europe, Japan, and other countries. As the population ages and as earlier detection become more common, PCA will become a more important focus of economic assessment.
• Cost comparisons among diagnostic or treatment modalities will remain challenging without standardized assessments of clinical outcomes that make evaluation of treatment effectiveness comparable across regimens.
• Overall key recommendations for future economic analyses should take into account the following factors:
-The absence of country-specific cost data across all endpoints, -The controversy over various screening, diagnostic, and staging options, -The disputed benefits of various primary and secondary treatments (ie., initial recurrent treatments), and -The lack of indirect cost data in non-U.S. countries.
Inter-paper comparison proved difficult, if not impossible due to the vast heterogeneity in study design, model inputs, and study endpoints.
• Aside from two cost-effectiveness studies on high-specificity endorectal coil 9 and magnetic resonance imaging, 10 there were no studies on the economic impact of other commonly used staging modalities such as bone scans, computed tomography, ProstaScint™ scanning, or lymphadenectomy.
Economic Evaluation of Treatment and Palliative Care
• Economic evaluations of treatments (N=43, 23.1%) focused primarily on androgen suppression therapy (N=13, 7.0%), as well as radical prostatectomy (N=10, 5.4%), radiation therapy (N=10, 5.4%), or combination therapies (N=10, 5.4%).
• Cost assessments of palliative care (N=21, 11.3%) focused primarily on hormonal therapy (N=16, 8.6%) rather than palliative chemotherapy, radiation therapy, or bisphosphonates.
• Follow-up data from the Prostate Testing for Cancer and Treatment (ProtecT) study may produce additional cost data on various treatments. The major objective of this study, which began in 1991, is to collect long-term data on the clinical effectiveness, cost-effectiveness, and acceptability of three treatment options for men with localized PCA, including active monitoring, RP, and radical RT.
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Economic Evaluation of Symptom Management
• Symptom management for urinary tract issues, erectile function, and pain associated with advanced PCA contribute significantly to the overall cost of managing PCA; however, few studies have reported cost estimates by key symptoms attributable to PCA.
• An economic model published by Grover SA et al. (1997) is the only article that addressed the costs for treating common complications related to curative treatment modalities.
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Bowel and rectal complications incurred the highest hospital length of stay, as well as the highest mean hospital costs.
• Patients remaining on hormonal therapy for long periods are at increased risk of developing bone complications including loss of cortical bone mass density, osteoporosis and fractures. Only one study calculated the median costs of fractures in a cohort of patients receiving hormonal therapy.
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Economic Evaluation of Pharmaceutical Preventions
• No pharmaceutical agents exist that are both clinically-and costeffective in the primary prevention of PCA.
• Despite preliminary findings from the Prostate Cancer Prevention Trial showing beneficial effects of the hormonal agent finasteride (Proscar ® ) in reducing the risk of PCA, the two independent economic studies of finasteride failed to show a favorable cost-effectiveness ratio for finasteride in the primary prevention of PCA, 14, 15 with the potential risk of impotence.
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Economic Impact of Recurrence after Treatment Failure
• The economic impact of recurrence can be measured by the costs of second-line, salvage therapies and their associated direct, non-medical costs.
• To date there have been at least four major clinical studies on cryosurgery, a process that involves inserting a frozen probe that destroys prostate tissue, two studies on permanent brachytherapy, a process that involves implanting small radioactive seeds directly into the prostate gland, and one study on radical prostatectomy following treatment failure with radiation therapy. [16] [17] [18] [19] [20] [21] [22] • All seven of these studies showed positive effects on patients who failed primary treatment.
• Studies examining the cost consequences of second line therapies after failing first line therapy were absent from the literature.
• Nearly half of the economic evaluations were retrospective, based on chart reviews and database analyses (N=89, 47.8%).
• Others were prospective evaluations based on clinical trials or observational studies (N=73, 39.2%), and economic modeling of PCA screening and treatment strategies (N=24, 12.9%).
• A total of 78 journals contained economic PCA literature, with the Journal of Urology contributing to the most number of articles (N=17) (see Figure 2 ).
Cost-of-Illness Studies
• Independent studies from the U.S., the U.K. (England and Wales), Australia, Canada, Germany, Netherlands, Scotland, and Sweden have reported the overall societal cost of PCA. Due to their vast differences in study designs, treatment patterns, prevalence rates, and other characteristics, any direct country-to-country comparisons should be cautioned. To date, there were no published cost-of-illness studies from other developed countries such as France, Italy, Spain, or Japan.
Costs per Patient and Cancer Stage
• A review of the published literature revealed a total of 11 articles on the cost per patient with PCA and 16 articles on the cost per treatment stage (eg., initial continuing, or terminal stages) and cancer stage (eg., localized vs. metastatic disease). All studies were conducted in the U.S. except for five studies conducted in Canada, Denmark, the Netherlands, Sweden, and the U.K.
Economic Evaluation of Mass Screening, Diagnosis, and Staging
• Economic studies of mass screening constituted 25 of the 186 articles selected for review, most of which reported the costs of a one-time screening program or the costs of screening per participant.
• Only two studies, both conducted in the U.S., evaluated the costs per life-year gained associated with mass screening programs. 7, 8 Of note, the American Urological Association, the American College of Radiology, and the American Foundation for Urologic Disease support mass PCA screening for the general population of men over 50 years of age.
• Studies from the U.S. (N=3), Sweden (N=5), Canada (N=1), the U.K. (N=1), and France (N=1) reported data on the cost per cancer detected with mass screening programs, with substantially varying degree of results.
• A total of 15 studies, including 12 conducted in the U.S., analyzed the costs and cost-effectiveness of various combinations of diagnostic techniques, including the prostate-specific antigen test, the digital rectal exam, the trans-rectal ultrasound sonography, the transurethral resection of the prostate, and the prostatic acid phosphatase analysis.
Literature Search
• Of 1,169 abstracts retrieved, 186 met the inclusion criteria, of which most (133 articles, 71.5%) were published since 1999 (see Figure 1 ).
• Although the incidence of PCA remained consistent in the U.S. over the past decade, 6 the importance of the economic assessment of PCA was reflected in the overall steady increase of publications over time, which has quadrupled since 1990, despite some yearly fluctuations seen in 1996, 1997, 2001 and 2003.
• A salient feature in this time trend was a dramatic increase in the number of articles published in 1994 and 1995. This rise in the number of articles may be attributed, in large part, to the introduction of the prostate-specific antigen (PSA) test and the subsequent heightened awareness of PCA screening. 
Gaps in the Economic Evaluation of Prostate Cancer
METHODS:
English-language abstracts and articles published between 1990 and mid-2005 were retrieved from MEDLINE, conference proceedings, and governmental databases using search terms "prostate cancer", "prostatic neoplasm", or similar, combined with a comprehensive list of cost-related search terms. Articles that provided economic data at an individual or societal level were retrieved in full text and analyzed by study type, design, endpoints, results, and other characteristics.
RESULTS:
Of 1169 abstracts retrieved, 186 met the inclusion criteria, of which most (133 articles, 71.5%) were published since 1999. Nearly half of the economic evaluations were retrospective, based on chart reviews and database analyses (89, 47.8%). Others were prospective evaluations based on clinical trials or observational studies (73, 39.2%), and economic modeling of PCA screening and treatment strategies (24, 12.9%). Cost-of-illness studies were completed in eight developed countries. Assessments of cost per treatment and/or per cancer stage (16, 8 .6%) and cost per patient (11, 5.9%) were conducted primarily in the U.S., as were cost studies of mass screening (25, 13.4%) and diagnostic modalities (15, 8.1% ). Cost evaluations of treatments (43, 23.1%) focused primarily on androgen suppression therapy (13, 7.0%), as well as radical prostatectomy (10, 5.4%), radiation therapy (10, 5.4%), or combination therapies (10, 5.4%). Cost assessments of palliative care (21, 11.3%) focused on hormonal therapy (16, 8.6% ). Studies of indirect costs, costs of pharmaceutical preventions (e.g. finasteride) and the economic impact of recurrence after treatment failure were scarce or unavailable.
CONCLUSIONS:
As the population ages and as earlier detection become more common, PCA is becoming a more important focus of economic assessment. Cost comparisons among diagnostic or treatment modalities will remain challenging without standardized assessments of clinical outcomes that make evaluation of treatment effectiveness comparable across regimens.
• Prostate Cancer (PCA) is a malignant tumor, characterized by uncontrolled cellular proliferation that affects more than 700,000 men a year worldwide, with more than 200,000 men a year in the United States (U.S).
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• PCA is the most commonly diagnosed form of cancer among men in the U.S. and the European Union (E.U.), excluding non-melanoma skin cancer. 1, 2 This disease primarily affects men 65 years and over. 3 • Based on the Montreal Prostate Cancer Model, the total lifetime burden of PCA in Canadian men 40 to 80 years of age was estimated to be approximately U.S. $8 billion (CAN $9.76 billion in 1996). 4 Costs associated with initial therapy contributed to the largest component (33%) of the total costs.
• In Sweden, the average lifetime per-patient cost of PCA was approximately U.S. $13,000 (SEK 79,000 in 1989), of which 50% of the total treatment cost was incurred during the year before death. 5 The two purposes of this study were to systematically review the medical literature:
(1) to assess:
• the overall economic impact of PCA,
• the direct costs associated with specific treatments, and
• the indirect costs of PCA associated with reduced work productivity.
(2) to synthesize and identify gaps in the economic literature of PCA.
• English-language abstracts and articles published between 1990 and mid-2005 were retrieved from computerized literature searches in MEDLINE, conference proceedings, and governmental databases using search terms "prostate cancer", "prostatic neoplasm", or similar, combined with a comprehensive list of cost-related search terms, including:
• Articles that provided economic data at an individual or societal level were retrieved in full text and analyzed by: 
